Why the study?
The exact molecular and cellular mechanisms of myosinopathies remain unclear.
Does the MYH1E321G mutation affect myosin conformation and force production in isolated equine myofibres?
Does the MYH1E321G mutation affect myosin conformation and force production in isolated equine myofibres?
Answers are grounded in this paper and cite their sources.
The MYH1E321G mutation causes a molecular and cellular hyper-contractile phenotype in equine myofibres, contributing to myosin heavy chain myopathy.
Myosinopathies are defined as a group of muscle disorders characterized by mutations in genes encoding myosin heavy chains. Their exact molecular and cellular mechanisms remain unclear. In the present study, we have focused our attention on a MYH1-related E321G amino acid substitution within the head region of the type IIx skeletal myosin heavy chain, associated with clinical signs of atrophy, inflammation and/or profound rhabdomyolysis, known as equine myosin heavy chain myopathy. We performed Mant-ATP chase experiments together with force measurements on isolated IIx myofibres from control horses (MYH1E321G−/−) and Quarter Horses homozygous (MYH1E321G+/+) or heterozygous (MYH1E321G+/−) for the E321G mutation. The single residue replacement did not affect the relaxed conformations of myosin molecules. Nevertheless, it significantly increased its active behaviour as proven by the higher maximal force production and Ca2+ sensitivity for MYH1E321G+/+ in comparison with MYH1E321G+/− and MYH1E321G−/− horses. Altogether, these findings indicate that, in the presence of the E321G mutation, a molecular and cellular hyper-contractile phenotype occurs which could contribute to the development of the myosin heavy chain myopathy.
No takes yet. Share an insight, caveat, or question.
Ochala et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: